ALISO VIEJO, Calif., Dec. 6 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that CEO Ronnie Andrews is scheduled to participate in a panel discussion titled "From Discovery To Diagnosis: Bringing New Testing Technologies To Market" at the RBC Capital Markets 2007 Healthcare Conference at 3:30 p.m. EST on Wednesday, December 12, 2007. The conference will be held at The Westin New York at Times Square in New York City on December 12.
A live webcast of the panel discussion at the conference will be available via a link provided at http://www.clarientinc.com/investor. An archived replay of the presentation will be available shortly after the presentation is concluded for a period of 30 days.
Clarient combines innovative technologies with world class expertise to assess and characterize cancer. Clarient's mission is to provide the services, resources and critical information to improve the quality and reduce the cost of patient care as well as accelerating the drug development process. The Company's principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies.
The rise of individualized medicine as the new direction in oncology has created the need for a centralized resource providing leading diagnostic technologies such as flow cytometry and molecular testing. Clarient is that resource, having created a state-of-the-art commercial cancer laboratory providing the most advanced oncology testing and drug development services available both onsite and over the web. Clarient is a Safeguard Scientifics, Inc. partner company. For more information, visit http://www.clarientinc.com.
Safeguard Scientifics, Inc. (NYSE: SFE), a holding company, builds
value in growth-stage technology and life sciences businesses. Safeguard
provides growth capital as well as a range of strategic, operating and
management resources to our partner companies. Safeguard participates in
growth buyout financings, including corporate spin-outs and management
buyouts, expansion financings, industry consolidations and early-stage
Allen & Caron, Inc.
|SOURCE Clarient, Inc.|
Copyright©2007 PR Newswire.
All rights reserved